fbpx

Issue of Equity on Exercise of Options/Vesting of Performance Share Awards

Cambridge, UK and Indianapolis, US – 21 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 9,000 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels (“Admission”) to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan, Unapproved Share option Plan and the vesting of awards under the Company’s Performance Share Plan.  The New Ordinary Shares will rank pari passu in all respects with the Company’s existing Ordinary Shares in issue.

Following issue of the New Ordinary Shares, the Company’s total issued share capital will consist of 53,947,756 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,947,756.

Contacts

Acacia Pharma Group plc
Mile Bolinder, CEO
Christine Soden, CFO
+44 1223 919760
IR@acaciapharma.com

Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

Nyheder

Video: Mød fem professorer, der har viet deres hjerne til andres
14. maj 2020
300 obduktioner er kernen i nyt dansk corona-projekt
8. maj 2020
Nu kan du søge om at blive Lundbeckfonden fellow
5. maj 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge